Deep Phenotyping in Cardiovascular Disease
- PDF / 251,798 Bytes
- 9 Pages / 595.276 x 790.866 pts Page_size
- 35 Downloads / 212 Views
(2021) 23:1
State-of-the-Art Informatics (C Stultz, Section Editor)
Deep Phenotyping in Cardiovascular Disease Sunil Kapur, MD1,2,* Calum A. MacRae, MD, PhD1,2 Address *,1 Cardiovascular Division, Brigham and Women’s Hospital, 75 Francis Street, Boston, MA, 02115, USA Email: [email protected] 2 Harvard Medical School, Boston, MA, USA
* Springer Science+Business Media, LLC, part of Springer Nature 2020
This article is part of the Topical Collection on State-of-the-Art Informatics Keywords Phenotyping I Phenomics I Deep phenotyping
Abstract Purpose of review To review the opportunities and challenges of phenotyping cardiovascular diseases in the modern era. Recent findings More recently, the emerging field of precision medicine aims to provide the best available care for each patient based on stratification into new disease subclasses with a common biological basis. The discovery of such subclasses at the correct scale and speed, as well as the translation of this knowledge into clinical care, will depend critically upon digital and computational resources to capture, store, and exchange phenotypic data and upon sophisticated algorithms to integrate these data with genomic variation, functional genomics profiles, and existing clinical information. Deep phenotyping can be defined as the comprehensive and precise analysis of phenotypic traits/abnormalities for such stratification. Recently, the term phenotype has largely been used to understand the “binary” output of a specific genetic code, in so-called genotype-phenotype correlations, but this has tended to constrain the use of the terminology to artificially dichotomized disease syndromes. Summary In the modern world, as we incorporate functional genomics into disease analysis, there has been a call to transform our understanding of individual patients via deep phenotyping or a more comprehensive study of the phenotype, i.e., multidimensional phenomics. Cardiovascular medicine, with its heterogeneity, prevalence, and therapeutic options, is a prime focus of precision medicine. In this article, we outline the current state of deep phenotyping in cardiovascular disease, including the rationale, current challenges, and opportunities for the future.
1
Page 2 of 9
Curr Treat Options Cardio Med
(2021) 23:1
Introduction Cardiovascular disease remains the leading cause of death worldwide accounting for ≈ 32% of all global deaths [1]. Today 92.1 million adults (9 1 in 3) in the United States have cardiovascular disease. By 2030, at least 44% of the adult population will be afflicted with cardiovascular disease [2]. The current approach to managing cardiovascular disease is based on a traditional reductionist approach. Patients are grouped into broad classifications using a predefined set of variables (many of which are based on legacy definitions from the nineteenth century). Interventions are then prescribed based on prior evidence from randomized controlled trials of specific drugs in specific disease classes, a process which typically has taken 15–20 years
Data Loading...
